CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

about

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.

P2860

Q51760779-0D9ED56A-129D-4610-AF30-907C301DE1EA

P2860

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

Item

http://www.wikidata.org/entity/Q47889283

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

@en

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

@nl

type

Item

label

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

@en

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

@nl

prefLabel

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

@en

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

@nl

P1476

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

@en

P2093

Andréas Bikfalvi

http://www.w3.org/2001/XMLSchema#string

Antoine Frangeul

http://www.w3.org/2001/XMLSchema#string

Audrey Claren

http://www.w3.org/2001/XMLSchema#string

Camillo Porta

http://www.w3.org/2001/XMLSchema#string

Damien Ambrosetti

http://www.w3.org/2001/XMLSchema#string

Delphine Borchiellini

http://www.w3.org/2001/XMLSchema#string

Emmanuel Chamorey

http://www.w3.org/2001/XMLSchema#string

Gilles Pagès

http://www.w3.org/2001/XMLSchema#string

Gérard Milano

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Ferrero

http://www.w3.org/2001/XMLSchema#string

P2860

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

CXCL7-Mediated Stimulation of Lymphangiogenic Factors VEGF-C, VEGF-D in Human Breast Cancer Cells

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

P2888

bjc.2017.276

P304

947-953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2017.276

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Arnaud Jacquel

Nathalie Rioux-Leclercq

Bernard Escudier

P577

2017-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28850564

http://www.w3.org/2001/XMLSchema#string

P932

5625677

http://www.w3.org/2001/XMLSchema#string

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

about

P2860

P2860

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932